TrialBritish journal of clinical pharmacology2025

Mild psoriasis as a suitable model for proof-of-mechanism in a phase 1B setting: Results from a double-blind placebo-controlled trial with guselkumab.

Jannik Rousel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.